SABCS 2024 | SABCS 2024 highlights: assessing the clinical impact of EMBER-3 and PATINA
Virginia Kaklamani, MD, UT Health San Antonio, San Antonio, TX, mentions the key highlights from the San Antonio Breast Cancer Symposium (SABCS) 2024. The EMBER-3 trial (NCT04975308) demonstrated that imlunestrant therapy led to significantly longer progression-free survival (PFS) than standard treatment for those with ESR1 (estrogen receptor 1) mutations in breast cancer. The PATINA study (NCT02947685) revealed that the addition of palbociclib to anti-HER2 and endocrine therapy led to a median PFS of 44 months in patients with HR+/HER2+ metastatic breast cancer. These findings can be translated towards the de-escalation of therapy for the appropriate patient populations in future clinical practices. This interview took place at the 2024 SABCS congress in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
